Skip to main content
. 2022 Mar 8;7(5):e157448. doi: 10.1172/jci.insight.157448

Figure 2. NHS–rmIL-12 treatment leads to abscopal control of distant tumors through IL-12R-dependent immunity.

Figure 2

(A) Naive WT B6 mice or mice that rejected MOC22 tumors after i.t. NHS–rmIL-12 treatment were challenged with MOC22 and followed for tumor growth. (B) WT B6 mice or IL-12Rb2–deficient (IL-12RKO) mice bearing established MOC22 tumors (n = 5/group) were treated with PBS control or low-dose i.t. NHS–rmIL-12. Significance determined by 2-way ANOVA. (C and D) Mice bearing established MOC22 tumors in bilateral flanks were treated with unilateral (right sided) low-dose i.t. NHS–rmIL-12, and both the treated (C) tumor and the untreated (D) tumors were followed for growth. Significance determined by 2-way ANOVA.